Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Clinical trial NCT06935188 · RECRUITING

Trial details

NCT number: NCT06935188
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start date: 2025-04-17
Primary completion: 2028-12-31
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.